- Overview
- Properties
- Genetics
- Related Genes
- Pathways
- Related Drugs
- Related Diseases
- Datasets
- Downloads/LinkOuts
Overview
| Generic Names: | Tamoxifen Citrate; Tamoxifene [INN-French]; Tamoxifeno [INN-Spanish]; Tamoxifenum [INN-Latin]; Trans-Tamoxifen |
|---|---|
| Trade Names: | Apo-Tamox; Citofen; Crisafeno; Diemon; Gen-Tamoxifen; Istubol; Kessar; Noltam; Nolvadex; Nolvadex-D; Nourytam; Novo-Tamoxifen; Oncomox; PMS-Tamoxifen; Retaxim; Tamizam; Tamofen; Tamone; Tamoxasta; Tamoxen; Valodex; Zemide |
| PharmGKB Accession Id: | PA451581 |
Description
One of the selective estrogen receptor modulators with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the endometrium. PubChem (source: Drug Bank)
Indication
Used for the treatment and prevention of breast cancer. (source: Drug Bank)
ATC Therapeutic Category
- L02BA:Anti-estrogens
Pharmacology, Interactions, and Contraindications
Mechanism Of Action
Tamoxifen binds to estrogen receptors (ER), inducing a conformational change in the receptor. This results in a blockage or change in the expression of estrogen dependent genes. The prolonged binding of tamoxifen to the nuclear chromatin of these results in reduced DNA polymerase activity, impaired thymidine utilization, blockade of estradiol uptake, and decreased estrogen response. It is likely that tamoxifen interacts with other coactivators or corepressors in the tissue and binds with different estrogen receptors, ER-alpha or ER-beta, producing both estrogenic and antiestrogenic effects. (source: Drug Bank)
Pharmacology
Tamoxifen belongs to a class of drugs called selective estrogen receptor modulators (SERMs), which have both estrogenic and antiestrogenic effects. Tamoxifen has the same nucleus as diethylstilbestrol but possesses an additional side chain (<i>trans</i> isomer) which accounts for its antiestrogenic activity. (source: Drug Bank)
Absorption, Distribution, Metabolism, Elimination & Toxicity
Biotransformation
Hepatic. Tamoxifen is extensively metabolized after oral administration. N-desmethyl tamoxifen is the major metabolite found in plasma. N-desmethyl tamoxifen activity is similar to tamoxifen. 4-Hydroxytamoxifen and a side chain primary alcohol derivative of tamoxifen have been identified as minor metabolites in plasma. Tamoxifen is a substrate of cytochrome P450 CYP3A4, CYP2C9 and CYP2D6, and an inhibitor of P-glycoprotein. (source: Drug Bank)
Toxicity
Signs observed at the highest doses following studies to determine LD50 in animals were respiratory difficulties and convulsions. (source: Drug Bank)
Isomeric SMILES Code:
CC/C(=C(\c1ccccc1)/c2ccc(cc2)OCCN(C)C)/c3ccccc3 (source: Drug Bank)
In-Depth Annotations (
)
-
rs6025
at chr1:167785673
in
F5
Associated with risk of venous thromboembolism (VTE).- Variant Name:
- F5:Factor V Leiden (FVL)
- Related Drugs:
- drotrecogin alfa, estrogens, hormonal contraceptives for systemic use, tamoxifen
- Related Diseases:
- Thromboembolism, venous thromboembolism
- Evidence:
-
http://www.pharmgkb.org/.../variant.jsp
-
rs2740574
at chr7:99220032
in
CYP3A,
CYP3A4
Defining variant for CYP3A4*1B; well studied, conflicting results on effect on gene transcription, no clear consensus on its significance for drug disposition, may be assocated with an increased risk of developing endometrial cancer after tamoxifen treatment.- Variant Name:
- CYP3A4:-392A>G; CYP3A4*1B
- Related Drugs:
- tamoxifen
- Related Diseases:
- Endometrial Neoplasms
- Evidence:
-
http://www.pharmgkb.org/.../variant.jsp
Curated Annotations (
)
-
rs351855
at chr5:176452849
in
FGFR4
This variant is associated with cancer progression and tumor cell motility. Patients carrying arg388 allele was associated with metastasis and poor prognosis in breast cancer and in colon cancer as well as poor clinical outcome for head and neck squamous cell carcinoma. possible association with sensitivity to cisplatin. It is associated with resistence to adjuvent systemic therapy in primary breast cancer.- Variant Name:
- FGFR4:GLY388ARG; FGFR4:Arg388
- Related Drugs:
- cisplatin, cyclophosphamide, fluorouracil, methotrexate, tamoxifen
- Related Diseases:
- Breast Neoplasms
- Evidence:
-
PMID:11830541
PMID:15197773
PMID:16822847
PMID:17084840
PMID:18487077
-
rs9340799
at chr6:152205074
in
ESR1
SNP is associated with tamoxifen-induced changes in total cholesterol and triglycerides in postmenopausal woman.- Variant Name:
- ESR1:c.454-351A>G; ESR1:XbaI; ESR1:rs9340799
- Related Drugs:
- tamoxifen
- Evidence:
-
PMID:17713466
-
rs11188072
at chr10:96509051
in
CYP2C19
This promoter variant is part of CYP2C19*17 haplotype, which causes increased acitivity and increased transcription of CYP2C19. Patients carrying this allele may exhibit a lack of response to commonly prescribed dosages of certain proton pump inhibitors (PPIs) and antidepressants, due to ultrarapid clearance of these drugs. CYP2C19*17 carriers are more likely to benifit from tamoxifen treatment.- Variant Name:
- CYP2C19: -3402C>T
- Related Drugs:
- amitriptyline, citalopram, clomipramine, escitalopram, omeprazole, proguanil, tamoxifen
- Evidence:
-
PMID:16413245
PMID:17625515
PMID:18294333
-
rs12248560
at chr10:96511647
in
CYP2C19
This promoter variant is part of CYP2C19*17 haplotype, which causes increased acitivity and increased transcription of CYP2C19. Patients carrying this allele may exhibit a lack of response to commonly prescribed dosages of certain proton pump inhibitors (PPIs) and antidepressants, due to ultrarapid clearance of these drugs. CYP2C19*17 carriers are more likely to benifit from tamoxifen treatment.- Variant Name:
- CYP2C19: -806C>T
- Related Drugs:
- amitriptyline, citalopram, clomipramine, escitalopram, omeprazole, proguanil, tamoxifen
- Evidence:
-
PMID:16413245
PMID:18024866
-
rs11023197
at chr11:14337574
in
RRAS2
In a study of tamoxifen treated breat cancer patients, carrying the T variant of RRAS2:(-582)C>T was associated with a higher frequency of relapse.- Variant Name:
- TC21 (RRAS2) -582C>T, RRAS2:(-582)C>T
- Related Drugs:
- tamoxifen
- Related Diseases:
- Breast Neoplasms
- Evidence:
-
PMID:19047159
-
rs4986938
at chr14:63769569
in
ESR2
SNP is associated with tamoxifen-induced changes in total cholesterol and triglycerides in postmenopausal woman.- Variant Name:
- ESR2-02
- Related Drugs:
- tamoxifen
- Evidence:
-
PMID:17713466
-
rs1135840
at chr22:40852557
in
CYP2D6
Risk or phenotype-associated allele: T. Phenotype: The CYP2D6*2A haplotype was associated with lower incidence of breast cancer on tamoxifen compared to placebo in a prevention study. The CYP2D6*2A allele may be associated with increased efficacy of tamoxifen. Study size: 182. Study population/ethnicity: Women in the Italian Tamoxifen Prevention trial, Caucasian, Italy. Significance metric(s): p = 0.0001. Type of association: CO.- Variant Name:
- CYP2D6:4180G>C, part of CYP2D6*2A an extensive metabolizer haplotype.
- Related Drugs:
- tamoxifen
- Related Diseases:
- Breast Neoplasms
- Evidence:
-
PMID:20309015
-
rs16947
at chr22:40853887
in
CYP2D6
Risk or phenotype-associated allele: T. Phenotype: The CYP2D6*2A haplotype was associated with lower incidence of breast cancer on tamoxifen compared to placebo in a prevention study. The CYP2D6*2A allele may be associated with increased efficacy of tamoxifen. Study size: 182. Study population/ethnicity: Women in the Italian Tamoxifen Prevention trial, Caucasian, Italy. Significance metric(s): p = 0.0001. Type of association: CO.- Variant Name:
- CYP2D6:2850C>T, part of CYP2D6*2A an extensive metabolizer haplotype.
- Related Drugs:
- tamoxifen
- Related Diseases:
- Breast Neoplasms
- Evidence:
-
PMID:20309015
-
rs3892097
at chr22:40854891
in
CYP2D6
In tamoxifen-treated patients, women with the CYP2D6 *4/*4 genotype tended to have a higher risk of disease relapse and a lower incidence of hot flashes.- Variant Name:
- CYP2D6:1846G>A, part of CYP2D6*4
- Related Drugs:
- tamoxifen
- Evidence:
-
PMID:16361630
http://preview.pharmgkb.org/.../variant.jsp
Variant names are different names that have been used in the literature and other resources to
refer to the same variant.
The following genes are in curated knowledge about this drug.
A list of non-curated publications that mention this drug along with other genes is available.
Drug Targets
| Gene | Description | |
|---|---|---|
| ABCB1 |
|
(source: Drug Bank) |
| ECGF1 |
|
(source: Drug Bank) |
| EPHX2 |
|
(source: Drug Bank) |
| ESR1 |
|
(source: Drug Bank) |
| ESR2 |
|
(source: Drug Bank) |
PharmGKB Curated Pathways
BioCarta Pathways†
Reactome Pathways†
†
External pathways not curated by PharmGKB.
The following drugs are in curated knowledge about this drug.
A list of non-curated publications that mention this drug along with other drugs is available.
Drug Interactions
| Drug | Description | |
|---|---|---|
| Nilotinib |
|
Nilotinib may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. (source: Drug Bank) |
| acenocoumarol |
|
Tamoxifen may increase the serum concentration of Acenocoumarol increasing the risk of bleeding. Concomitant therapy should be avoided. (source: Drug Bank) |
| aminoglutethimide |
|
Aminoglutethimide may increase Tamoxifen clearance decreasing its therapeutic effect. Consider alternate therapy or monitor for changes in Tamoxifen effects when Aminoglutethimide is initiated, discontinued or dose changed. (source: Drug Bank) |
| amiodarone |
|
Amiodarone may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. (source: Drug Bank) |
| amprenavir |
|
Amprenavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. (source: Drug Bank) |
| atazanavir |
|
Atazanavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. (source: Drug Bank) |
| capecitabine |
|
Capecitabine may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Capecitabine is initiated, discontinued or dose changed. (source: Drug Bank) |
| chloroquine |
|
Chloroquine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. (source: Drug Bank) |
| chlorpromazine |
|
Chlorpromazine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided. (source: Drug Bank) |
| cimetidine |
|
Cimetidine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. (source: Drug Bank) |
| cinacalcet |
|
Cinacalcet may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided. (source: Drug Bank) |
| clarithromycin |
|
Clarithromycin may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. (source: Drug Bank) |
| clomipramine |
|
Clomipramine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. (source: Drug Bank) |
| clozapine |
|
Clozapine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. (source: Drug Bank) |
| cocaine |
|
Cocaine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided. (source: Drug Bank) |
| conivaptan |
|
Conivaptan may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. (source: Drug Bank) |
| darifenacin |
|
Darifenacin may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. (source: Drug Bank) |
| darunavir |
|
Darunavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. (source: Drug Bank) |
| delavirdine |
|
Delavirdine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided. (source: Drug Bank) |
| desipramine |
|
Desipramine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. (source: Drug Bank) |
| diphenhydramine |
|
Diphenhydramine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. (source: Drug Bank) |
| duloxetine |
|
Duloxetine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. (source: Drug Bank) |
| floxuridine |
|
Floxuridine may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Floxiridine is initiated, discontinued or dose changed. (source: Drug Bank) |
| fluconazole |
|
Fluconzole may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Fluconazole is initiated, discontinued or dose changed. (source: Drug Bank) |
| fluorouracil |
|
Fluorouracil may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Fluorouracil is initiated, discontinued or dose changed. (source: Drug Bank) |
| fluoxetine |
|
Fluoxetine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided. (source: Drug Bank) |
| flurbiprofen |
|
Flurbiprofen may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Flurbiprofen is initiated, discontinued or dose changed. (source: Drug Bank) |
| fosamprenavir |
|
Fosmprenavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. (source: Drug Bank) |
| gemfibrozil |
|
Gemfibrozil may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Gemfibrozil is initiated, discontinued or dose changed. (source: Drug Bank) |
| haloperidol |
|
Haloperidol may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. (source: Drug Bank) |
| ibuprofen |
|
Ibuprofen may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Ibuprofen is initiated, discontinued or dose changed. (source: Drug Bank) |
| imatinib |
|
Imatinib may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Imatinib may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Imatinib is initiated, discontinued or dose changed. (source: Drug Bank) |
| imipramine |
|
Imipramine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. (source: Drug Bank) |
| indinavir |
|
Indinavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. (source: Drug Bank) |
| indomethacin |
|
Indomethacin may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Indomethacin is initiated, discontinued or dose changed. (source: Drug Bank) |
| isoniazid |
|
Isoniazid may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Isoniazid may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Isoniazid is initiated, discontinued or dose changed. (source: Drug Bank) |
| itraconazole |
|
Itraconazole may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. (source: Drug Bank) |
| ketoconazole |
|
Ketoconazole may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Ketoconazole may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank) |
| lidocaine |
|
Lidocaine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. (source: Drug Bank) |
| lopinavir |
|
Lopinavir may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided. (source: Drug Bank) |
| methadone |
|
Methadone may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. (source: Drug Bank) |
| methimazole |
|
Methimazole may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. (source: Drug Bank) |
| miconazole |
|
Miconazole may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided. (source: Drug Bank) |
| nefazodone |
|
Nefazodone may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. (source: Drug Bank) |
| nelfinavir |
|
Nelfinavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. (source: Drug Bank) |
| nicardipine |
|
Nicardipine may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Nicardipine may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Nicardipine is initiated, discontinued or dose changed. (source: Drug Bank) |
| paroxetine |
|
Paroxetine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided. (source: Drug Bank) |
| pergolide |
|
Pergolide may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided. (source: Drug Bank) |
| pioglitazone |
|
Pioglitazone may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. (source: Drug Bank) |
| piroxicam |
|
Piroxicam may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Piroxicam is initiated, discontinued or dose changed. (source: Drug Bank) |
| posaconazole |
|
Posaconazole may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. (source: Drug Bank) |
| pyrimethamine |
|
Pyrimethamine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. (source: Drug Bank) |
| quinidine |
|
Quinidine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided. (source: Drug Bank) |
| quinine |
|
Quinine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. (source: Drug Bank) |
| ranolazine |
|
Ranolazine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. (source: Drug Bank) |
| ritonavir |
|
Ritonavir may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided. (source: Drug Bank) |
| saquinavir |
|
Saquinavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. (source: Drug Bank) |
| sertraline |
|
Sertraline may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. (source: Drug Bank) |
| sulfadiazine |
|
Sulfadiazine may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Sulfadiazine is initiated, discontinued or dose changed. (source: Drug Bank) |
| sulfisoxazole |
|
Sulfisoxazole may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Sulfisoxazole is initiated, discontinued or dose changed. (source: Drug Bank) |
| telithromycin |
|
Telithromycin may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. (source: Drug Bank) |
| terbinafine |
|
Terbinafine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided. (source: Drug Bank) |
| thioridazine |
|
Thioridazine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. (source: Drug Bank) |
| ticlopidine |
|
Ticlopidine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. (source: Drug Bank) |
| tolbutamide |
|
Tolbutamide may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Tolbutamide is initiated, discontinued or dose changed. (source: Drug Bank) |
| topotecan |
|
Tamoxifen may increase serum concentrations of oral Topotecan. Concomitant therapy should be avoided. (source: Drug Bank) |
| tranylcypromine |
|
Tranylcypromine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. (source: Drug Bank) |
| trazodone |
|
Trazodone may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. (source: Drug Bank) |
| voriconazole |
|
Voriconazole may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. (source: Drug Bank) |
| warfarin |
|
Tamoxifen may increase the serum concentration of Warfarin increasing the risk of bleeding. Concomitant therapy should be avoided. (source: Drug Bank) |
Curated Information
The following diseases are in curated knowledge about this drug.
| Disease | Relationship | Evidence | |
|---|---|---|---|
|
Breast Neoplasms |
|
Publications, Variants |
|
|
Death |
|
Publications |
|
|
Depression |
|
Publications |
|
|
estrogen-dependent carcinogenesis |
|
Publications |
|
|
Heart Diseases |
|
Publications |
|
|
Hot Flashes |
|
Publications |
|
|
Lung Neoplasms |
|
Publications |
|
|
Neoplasms |
|
Publications |
|
|
Ovarian Neoplasms |
|
Publications |
|
|
Rett Syndrome |
|
Publications |
|
|
Schizophrenia |
|
Publications |
Non-Curated Information
A list of non-curated publications that mention this drug along with other diseases is available.
Curated Phenotype Datasets
These datasets are sorted alphabetically by title.
- Bone mineral density in tamoxifen patients
- PD
Submitted by David Flockhart, MD, PhD involving CYP2C9, CYP2D6, CYP3A5, ESR1, ESR2, SULT1A1, tamoxifen, and Breast Neoplasms - Hot flashes in tamoxifen patients
- PD
Submitted by David Flockhart, MD, PhD involving CYP2C9, CYP2D6, CYP3A5, ESR1, ESR2, SULT1A1, tamoxifen, and Breast Neoplasms - Lipid measurements in tamoxifen study
- PD
- GN
Submitted by David Flockhart, MD, PhD involving CYP2D6, CYP3A5, ESR1, ESR2, NOS3, tamoxifen, and Breast Neoplasms - Lipid measurements in tamoxifen study - set 2
- PD
- PK
- GN
Submitted by David Flockhart, MD, PhD involving CYP2C9, CYP2D6, CYP3A5, ESR1, ESR2, SULT1A1, tamoxifen, and Breast Neoplasms - Pharmacokinetics of Tamoxifen at 4 months
- PK
Submitted by David Flockhart, MD, PhD involving CYP2C9, CYP2D6, CYP3A5, ESR1, ESR2, SULT1A1, tamoxifen, and Breast Neoplasms - Thyroid binding globulin in tamoxifen patients
- PD
Submitted by David Flockhart, MD, PhD involving CYP2C9, CYP2D6, CYP3A5, ESR1, ESR2, SULT1A1, tamoxifen, and Breast Neoplasms
Additional Datasets
These datasets are minimally curated and are sorted alphabetically by title.
Downloads
You must sign in before you can download data.
LinkOuts
Common Searches
Search PubMed
Search Medline Plus
Search PubChem
Search CTD
Non-Curated Publications
A list of non-curated publications that mention this drug is available.